Scarica l'app Stockscreener
2.16
24.14%
0.42
Dopo l'orario di chiusura:
2.13
-0.03
-1.39%
Precedente Chiudi:
$1.74
Aprire:
$1.81
Volume 24 ore:
9.34M
Relative Volume:
1.08
Capitalizzazione di mercato:
$449.76M
Reddito:
$176.23M
Utile/perdita netta:
$-257.83M
Rapporto P/E:
-1.4897
EPS:
-1.45
Flusso di cassa netto:
$-246.00M
1 W Prestazione:
+8.00%
1M Prestazione:
+176.57%
6M Prestazione:
+288.63%
1 anno Prestazione:
+369.57%
Intervallo 1D:
$1.72
$2.175
Intervallo di 1 settimana:
$1.68
$2.175
Portata 52W:
$0.2911
$2.30
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Nome
Sangamo Therapeutics Inc
Settore
Industria
Telefono
(510) 970-6000
Indirizzo
501 CANAL BLVD., RICHMOND, CA
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-04-28 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-01-07 | Ripresa | Guggenheim | Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-12-16 | Ripresa | H.C. Wainwright | Buy |
| 2020-09-08 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | SunTrust | Buy |
| 2019-08-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2018-10-10 | Iniziato | Guggenheim | Buy |
| 2018-06-20 | Iniziato | BofA/Merrill | Buy |
| 2017-11-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2016-11-01 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-10-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-10-23 | Ripresa | Jefferies | Buy |
| 2013-05-03 | Iniziato | BioLogic Equity Research | Sell |
| 2011-02-23 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-07-29 | Reiterato | Wedbush | Outperform |
| 2009-10-19 | Iniziato | Brean Murray | Sell |
| 2009-10-07 | Reiterato | Leerink Swann | Outperform |
| 2009-08-25 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
Sangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Sangamo Therapeutics (NASDAQ:SGMO) Stock - MarketBeat
Vanguard Group Inc's Strategic Reduction in Sangamo Therapeutics Inc - GuruFocus.com
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - StockTitan
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance
Sangamo Therapeutics (NASDAQ:SGMO) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Sangamo Therapeutics (NASDAQ:SGMO) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate - Genetic Engineering & Biotechnology News
Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads - Investing.com
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads By Investing.com - Investing.com UK
4 Analysts Have This To Say About Sangamo Therapeutics - Benzinga
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St
Sangamo shares jump as FDA clears faster gene therapy pathway - The Pharma Letter
Sangamo stock rallies 37% on FDA update for Fabry disease drug - MSN
Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart
Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Traders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat
Sangamo Therapeutics Shares Jump After FDA Discussion on Accelerated Approval Pathway for Fabry Disease Drug - MarketWatch
Sangamo stock rallies 37% on FDA update for Fabry disease drug (NASDAQ:SGMO) - Seeking Alpha
CBER’s lean into accelerated approval slashes three years from Sangamo gene therapy - BioCentury
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 - Business Wire
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec… Trifecta Soon? (NASDAQ:SGMO) - Seeking Alpha
Cubist Systematic Strategies LLC Purchases Shares of 185,813 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Are Smart Investors Making the Right Decision? Sangamo Therapeutics Inc (SGMO) - SETE News
Sangamo Therapeutics Inc Inc. (SGMO) Price Performance: The Role of Supply and Demand - The InvestChronicle
Observations on the Sangamo Therapeutics Inc (NASDAQ:SGMO) Growth Curve - US Post News
Sangamo Therapeutics Inc (SGMO) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Sangamo Therapeutics Inc [SGMO] Investment Guide: What You Need to Know - Knox Daily
The growth track for Sangamo Therapeutics Inc (SGMO) has changed recently - SETE News
Genome Editing Market Analysis 2031, Competitive Landscape, Factors, Factors And Competition | Horizon Discovery Group, Lonza, Merck KGaA, Sangamo Therapeutics, Thermo Fisher Scientific – Times-BD24 - Times-BD24
A closer look at Sangamo Therapeutics Inc’s (SGMO) current quarter earnings projections - US Post News
Balance Sheet Breakdown: Sangamo Therapeutics Inc (SGMO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Acquired by Renaissance Technologies LLC - MarketBeat
Sangamo seeks court validation for stock amendment - Investing.com India
Sangamo seeks court validation for stock amendment By Investing.com - Investing.com UK
Sangamo Therapeutics Seeks Court Approval for Stock Amendment - TipRanks
Investing in Sangamo Therapeutics Inc (SGMO) Is Getting More Attractive - Knox Daily
5 Best Stem Cell Companies to Invest In (November 2024) - Securities.io
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces pivotal year By Investing.com - Investing.com South Africa
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces pivotal year - Investing.com India
Point72 Asia Singapore Pte. Ltd. Makes New $89,000 Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Sangamo Therapeutics (NASDAQ:SGMO) Shares Cross Above 200-Day Moving Average of $0.64 - MarketBeat
Armistice Capital LLC Sells 2,898,477 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Passes Above 200-Day Moving Average of $0.64 - Defense World
Haemophilia Gene Therapy Market Recent Developments & Growth Opportunities 2022-2030 | BioMarin Pharmaceuticals Inc., F Hoffmann-La Roche AG, Freeline Therapeutics, Pfizer, Sangamo Therapeutics Inc. – Cauverynews - Cauverynews
A Tale of Resilience: Sangamo Therapeutics Inc Amid Stock Market Turbulence - The InvestChronicle
Retail investors who hold 56% of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) gained 13%, institutions profited as well - Simply Wall St
Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week - Yahoo Finance
Sangamo Therapeutics Target of Unusually High Options Trading (NASDAQ:SGMO) - MarketBeat
Press Release Service: Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex PharmaceuticalsResearchAndMarkets.comC - CRISPR Medicine News
Sangamo Therapeutics Inc Azioni (SGMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):